Innate Pharma S.A. (IPHYF)
USD 2.9
(0.0%)
USD 2.9
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 39.89 Million EUR | -5.58% |
| 2022 | 42.25 Million EUR | -4.52% |
| 2021 | 44.25 Million EUR | 131.84% |
| 2020 | 19.08 Million EUR | 1.94% |
| 2019 | 18.72 Million EUR | 314.04% |
| 2018 | 4.52 Million EUR | -22.89% |
| 2017 | 5.86 Million EUR | 10.08% |
| 2016 | 5.32 Million EUR | 41.9% |
| 2015 | 3.75 Million EUR | -10.75% |
| 2014 | 4.2 Million EUR | -12.72% |
| 2013 | 4.81 Million EUR | 6.97% |
| 2012 | 4.5 Million EUR | -65.93% |
| 2011 | 13.22 Million EUR | 94.83% |
| 2010 | 6.78 Million EUR | -10.17% |
| 2009 | 7.55 Million EUR | 0.0% |
| 2008 | - EUR | 0.0% |
| 2007 | - EUR | -100.0% |
| 2006 | 3.3 Million EUR | 470.34% |
| 2005 | 580 Thousand EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 34.91 Million EUR | 1.68% |
| 2024 Q1 | 34.91 Million EUR | -12.48% |
| 2023 Q1 | 40.1 Million EUR | -5.09% |
| 2023 Q2 | 40.65 Million EUR | 1.39% |
| 2023 Q4 | 39.89 Million EUR | 1.23% |
| 2023 Q3 | 39.4 Million EUR | -3.07% |
| 2023 FY | 39.89 Million EUR | -5.58% |
| 2022 Q2 | 43.37 Million EUR | 1.96% |
| 2022 Q1 | 42.54 Million EUR | -3.87% |
| 2022 FY | 42.25 Million EUR | -4.52% |
| 2022 Q3 | 41.42 Million EUR | -4.49% |
| 2022 Q4 | 42.25 Million EUR | 1.99% |
| 2021 Q3 | 43.44 Million EUR | 163.28% |
| 2021 FY | 44.25 Million EUR | 131.84% |
| 2021 Q4 | 44.25 Million EUR | 1.85% |
| 2021 Q2 | 16.5 Million EUR | 5.36% |
| 2021 Q1 | 15.66 Million EUR | -17.94% |
| 2020 Q2 | 18.81 Million EUR | 4.13% |
| 2020 Q4 | 19.08 Million EUR | 4.24% |
| 2020 FY | 19.08 Million EUR | 1.94% |
| 2020 Q1 | 18.07 Million EUR | -3.49% |
| 2020 Q3 | 18.31 Million EUR | -2.69% |
| 2019 Q4 | 18.72 Million EUR | 3.52% |
| 2019 FY | 18.72 Million EUR | 314.04% |
| 2019 Q1 | 3.74 Million EUR | -17.18% |
| 2019 Q2 | 4.95 Million EUR | 32.42% |
| 2019 Q3 | 18.08 Million EUR | 264.71% |
| 2018 FY | 4.52 Million EUR | -22.89% |
| 2018 Q4 | 4.52 Million EUR | 26.7% |
| 2018 Q3 | 3.56 Million EUR | -31.81% |
| 2018 Q2 | 5.23 Million EUR | 23.04% |
| 2018 Q1 | 4.25 Million EUR | -27.46% |
| 2017 FY | 5.86 Million EUR | 10.08% |
| 2017 Q4 | 5.86 Million EUR | 18.46% |
| 2017 Q3 | 4.95 Million EUR | 6.2% |
| 2017 Q2 | 4.66 Million EUR | 24.0% |
| 2017 Q1 | 3.75 Million EUR | -29.43% |
| 2016 Q3 | 4.43 Million EUR | 8.67% |
| 2016 FY | 5.32 Million EUR | 41.9% |
| 2016 Q4 | 5.32 Million EUR | 20.03% |
| 2016 Q2 | 4.08 Million EUR | 15.63% |
| 2016 Q1 | 3.53 Million EUR | -5.91% |
| 2015 Q1 | 3.52 Million EUR | -16.29% |
| 2015 Q2 | 3.98 Million EUR | 13.12% |
| 2015 Q3 | 3.28 Million EUR | -17.6% |
| 2015 Q4 | 3.75 Million EUR | 14.38% |
| 2015 FY | 3.75 Million EUR | -10.75% |
| 2014 Q2 | 4.42 Million EUR | 11.15% |
| 2014 Q3 | 3.75 Million EUR | -15.19% |
| 2014 Q4 | 4.2 Million EUR | 12.07% |
| 2014 FY | 4.2 Million EUR | -12.72% |
| 2014 Q1 | 3.98 Million EUR | -17.39% |
| 2013 Q2 | 4.08 Million EUR | 15.51% |
| 2013 FY | 4.81 Million EUR | 6.97% |
| 2013 Q4 | 4.81 Million EUR | 11.11% |
| 2013 Q3 | 4.33 Million EUR | 6.09% |
| 2013 Q1 | 3.53 Million EUR | -21.44% |
| 2012 Q4 | 4.5 Million EUR | 0.0% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 FY | 4.5 Million EUR | -65.93% |
| 2012 Q3 | - EUR | 0.0% |
| 2011 Q4 | 13.22 Million EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2011 FY | 13.22 Million EUR | 94.83% |
| 2010 Q2 | - EUR | 0.0% |
| 2010 FY | 6.78 Million EUR | -10.17% |
| 2010 Q4 | 6.78 Million EUR | 0.0% |
| 2009 FY | 7.55 Million EUR | 0.0% |
| 2009 Q4 | 7.55 Million EUR | 0.0% |
| 2008 FY | - EUR | 0.0% |
| 2007 FY | - EUR | -100.0% |
| 2006 FY | 3.3 Million EUR | 470.34% |
| 2005 FY | 580 Thousand EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -2658.244% |
| CSL Limited | 12.18 Billion USD | 99.673% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 3.179% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -867.817% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -9827.361% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 8.023% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -34.017% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -4106.92% |
| Mesoblast Limited | 118.7 Million USD | 66.392% |
| Marizyme, Inc. | 18.71 Million USD | -113.132% |
| Genus plc | 233.1 Million USD | 82.886% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -1261.356% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -2869.148% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -5219.067% |
| ContraFect Corporation | 2.88 Million USD | -1284.693% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -29344.153% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| IMV Inc. | 28.88 Million USD | -38.115% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -605.028% |
| MultiCell Technologies, Inc. | 202.58 USD | -19692367.173% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 30.608% |
| EV Biologics, Inc. | 1.49 Million USD | -2568.873% |
| Q BioMed Inc. | 4.1 Million USD | -870.637% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -20.519% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -3147.661% |
| Biomind Labs Inc. | 735.54 Thousand USD | -5323.62% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -206.94% |
| Skye Bioscience, Inc. | 4.61 Million USD | -764.371% |
| SQZ Biotechnologies Company | 27.47 Million USD | -45.219% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -28089.347% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -579.482% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -1615.123% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -155011.007% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -6231.448% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 76.745% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -4392.131% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -1666.442% |
| GB Sciences, Inc. | 1.75 Million USD | -2167.541% |
| Alpha Cognition Inc. | 1.22 Million USD | -3168.921% |
| argenx SE | 20 Million USD | -99.465% |
| HST Global, Inc. | 98.31 Thousand USD | -40475.067% |
| Halberd Corporation | 150 Thousand USD | -26495.333% |
| Enzolytics Inc. | 996.33 Thousand USD | -3903.963% |
| Resverlogix Corp. | 6.49 Million USD | -514.589% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -15508.079% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 12.439% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 41.024% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -1218.258% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -464.033% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -10990.323% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -1372.771% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| ONE Bio Corp. | 19.71 Million USD | -102.348% |
| Zenith Capital Corp. | 10.22 Thousand USD | -390051.589% |
| Genscript Biotech Corporation | 417.73 Million USD | 90.45% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -19785.253% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -1563.786% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -17298.415% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -26736.143% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -15939.321% |
| Agentix Corp. | 50 Thousand USD | -79686.0% |
| Adynxx, Inc. | - USD | -Infinity% |
| Kadimastem Ltd | 891.22 Thousand USD | -4376.193% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -96.247% |
| BioStem Technologies, Inc. | 4.71 Million USD | -746.73% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -15845.592% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| LadRx Corporation | 33.6 Thousand USD | -118607.969% |
| Cell Source, Inc. | 9.25 Million USD | -331.081% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -5175.428% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -5175.428% |
| NovAccess Global Inc. | 2.19 Million USD | -1713.417% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | -17368.046% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -18808.875% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -700.582% |
| CytoDyn Inc. | 30.07 Million USD | -32.641% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -11238.167% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -410.143% |
| SYBLEU INC | 477.5 Thousand USD | -8254.555% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -32465.714% |
| Rebus Holdings, Inc. | 310 Thousand USD | -12768.71% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -742.463% |
| Mobile Lads Corp. | 484.28 Thousand USD | -8137.522% |
| International Stem Cell Corporation | 4.17 Million USD | -854.835% |
| Bioxytran, Inc. | 1.92 Million USD | -1972.364% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -63817.774% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -1729.199% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -379.714% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -364.683% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -2464.676% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -14785.448% |
| Neutra Corp. | 54.15 Thousand USD | -73563.121% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -2079.945% |
| PureTech Health plc | 25.51 Million USD | -56.37% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -3158.63% |
| IXICO plc | 472.02 Thousand USD | -8351.495% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -157.358% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 35.928% |
| CSL Limited | 12.18 Billion USD | 99.673% |
| Cellectis S.A. | 92.77 Million USD | 57.001% |